Thelansis

Charcot-Marie-Tooth Disease Type 2C (CMT2C) Market Outlook Thelansis’s “Charcot-Marie-Tooth Disease Type 2C (CMT2C) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth Disease Type 2C (CMT2C) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Charcot-Marie-Tooth Disease Type 2C (CMT2C) Overview Charcot-Marie-Tooth disease type 2C (CMT2C) is a rare autosomal dominant axonal peripheral neuropathy caused by gain-of-function mutations in the TRPV4 gene, encoding a calcium-permeable mechanosensitive cation channel, resulting in aberrant calcium influx, motor neuron toxicity, and progressive axonal degeneration. Ner...

Muscle-Invasive Bladder Cancer (MIBC) Market Outlook Thelansis’s “Muscle-Invasive Bladder Cancer (MIBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Muscle-Invasive Bladder Cancer (MIBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Muscle-Invasive Bladder Cancer (MIBC) Overview Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy characterized by the infiltration of urothelial carcinoma into the detrusor muscle layer of the bladder wall, carrying a high risk of systemic micrometastasis. Clinically, patients most frequently present with painless gross hematuria, irritative voiding symptoms, or pelvic pain...

Neuroendocrine Prostate Cancer (NEPC) Market Outlook Thelansis’s “Neuroendocrine Prostate Cancer (NEPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Prostate Cancer (NEPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Neuroendocrine Prostate Cancer (NEPC) Overview Neuroendocrine prostate cancer (NEPC) is an aggressive, highly lethal variant of prostate cancer characterized by a transition from luminal adenocarcinoma to a neuroendocrine phenotype. While it can arise de novo, it most commonly develops as treatment-emergent neuroendocrine prostate cancer (t-NEPC), an adaptive resistance mechanism driven by...

Advanced Melanoma Market Outlook Thelansis’s “Advanced Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced Melanoma Overview Advanced melanoma is an aggressive skin cancer defined by unresectable stage III or metastatic stage IV disease, driven by uncontrolled proliferation of melanocytes and frequent genomic alterations such as BRAF, NRAS, and NF1 mutations. Clinically, it presents with progressive cutaneous, nodal, or visceral metastases, often involving lung, liver, or brain. Diagnosis requires histopathology with immunohistochemical markers...

Primary IgA Nephropathy (IgAN) Market Outlook Thelansis’s “Primary IgA Nephropathy (IgAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary IgA Nephropathy (IgAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary IgA Nephropathy (IgAN) Overview Primary IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally, characterized by progressive renal impairment driven by glomerular deposition of galactose-deficient IgA1 (Gd-IgA1) immune complexes. Pathogenesis follows a multi-hit model where mesangial deposition triggers inflammation, glomerulosclerosis, and interstitial fibrosis, presenting clini...

Bronchiectasis Emerging Therapy and TPP Insights Thelansis’s “Bronchiectasis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Bronchiectasis Overview Bronchiectasis is a chronic, progressive structural lung disease characterised by irreversible pathological dilatation and destruction of the bronchial walls — resulting from a self-perpetuating cycle of recurrent infection, neutrophilic airway inflammation, and impaired mucociliary clearance — producing permanently damaged, mucus-laden airways susceptible to chronic bacterial colonisation. Underlying aetiologies are diverse, encompassing post-infectious damage, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency states, allergic bronchopulmonary aspergillosis, connective tissue d...

Non-Tuberculous Mycobacterial (NTM) Emerging Therapy and TPP Insights Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Non-Tuberculous Mycobacterial (NTM) Overview Non-tuberculous mycobacterial (NTM) pulmonary disease is a chronic, progressive, and highly morbid respiratory infection caused by ubiquitous environmental mycobacteria, most predominantly the Mycobacterium avium complex (MAC) and the highly resistant Mycobacterium abscessus . The disease opportunistically exploits compromised structural lung architecture—most notably in patients with underlying bronchiectasis, cystic fibrosis, or chronic obstructive pulmonary disease (COPD)—driving relentless granulomatous inflammation and irr...